WEBULL
WebtradeDownload

Is Maravai LifeSciences Holdings (MRVI) Cheap After Its Recovery Narrative Pushed Shares To $7.37?

Simply Wall St · 3d ago

Maravai LifeSciences Holdings: recent performance snapshot

Maravai LifeSciences Holdings (MRVI) has drawn fresh attention after recent trading left the shares at US$7.37 as of 23 September 2026. The move caps a mixed pattern across the past month and past 3 months.

The stock declined 12.6% over the past month but gained 20.4% over the past 3 months and is up 116.8% year to date. Over the past year, total return reached 170.9%, while the 3 year and 5 year total returns show declines of 24.5% and 84.8% respectively.

For Maravai LifeSciences Holdings, the picture is split. In the short term, the share price has swung around, with a 7 day share price return of 7.8% but a 30 day share price return that is down 12.6%. Over a longer period, momentum has been strong, with a year to date share price gain of 116.8% and a 1 year total shareholder return of 171.0%, even though the 3 year and 5 year total shareholder returns remain weak, both showing declines.

Compare Maravai LifeSciences Holdings' sharp rebound with a hand picked group of resilient businesses in the 31 resilient stocks with low risk scores to see how other lower risk profiles have held up this year.

Maravai LifeSciences Holdings has ripped higher this year after a tough multi year stretch, which leaves you weighing a quick entry against waiting for the next pullback. So what are you really paying for at US$7.37?

Most Popular Narrative: 4% Overvalued

At a last close of $7.37, the most followed narrative pegs fair value for Maravai LifeSciences Holdings at $7.10, implying the stock trades modestly above that estimate while still baking in a meaningful recovery story.

The company's restructuring plan streamlining operations, consolidating executive roles, and targeting over $50 million in annualized cost savings is expected to significantly lower SG&A expenses, restore EBITDA margins, and support a return to positive free cash flow by the second half of 2026, directly improving earnings. Expansion and innovation in the Biologics Safety Testing (BST) segment, particularly through new analytical product launches and further penetration in cell and gene therapy markets, are poised to leverage the ongoing global growth and regulatory focus in these therapeutic areas, supporting recurring revenue growth and margin stability.

See why 2 investors see Maravai LifeSciences Holdings as 4% overvalued.

Result: Fair Value of $7.10 (OVERVALUED)

Still, recent revenue softness and ongoing net losses mean that any stumble in scaling the new Jupiter GMP facility could quickly challenge this Maravai LifeSciences Holdings recovery narrative.

Find out about the key risks to this Maravai LifeSciences Holdings narrative.

Another View: SWS DCF Model Flags Big Upside

Analyst targets suggest Maravai LifeSciences Holdings is only slightly ahead of fair value at $7.10, but the SWS DCF model presents a different perspective. On that cash flow view, MRVI is trading about 51% below an estimated future cash flow value of $15.14, which some investors may see as a significant gap.

If the story rests heavily on future cash generation rather than earnings multiples, the key question becomes straightforward: Which set of assumptions do you consider more reliable, the analyst price target or the long term cash flow model?

Look into how the SWS DCF model arrives at its fair value.

MRVI Discounted Cash Flow as at Sep 2026
MRVI Discounted Cash Flow as at Sep 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Maravai LifeSciences Holdings for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 30 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed signals run through the Maravai LifeSciences Holdings story, so move quickly to review the numbers, weigh the trade offs, and assess the 1 key reward and 1 important warning sign.

Looking for more investment ideas beyond Maravai LifeSciences Holdings?

If Maravai LifeSciences Holdings has sharpened your focus on valuation and momentum, broaden your watchlist with other ideas that could suit different goals and risk levels.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.